Advertisement
Home »

Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?

Apr 08, 2024

ABOUT THE EXPERTS

  • Anna Kenseth

    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.

    Dominika Kantorova

    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.

    Mikyung Kelly Seo

    Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ks2024@cam.ac.uk.

    Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom. ks2024@cam.ac.uk.

    Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, United Kingdom. ks2024@cam.ac.uk.

    Eline Aas

    Department of Health Management and Health Economics, Institute of Health and Society,, University of Oslo, Oslo, Norway.

    John Cairns

    Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.

    David Kerr

    Radcliffe Department of Medicine, Oxford University, Oxford, UK.

    Hanne Askautrud

    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.

    Jørn Evert Jacobsen

    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.

    Department of Research and Innovation, Vestfold Hospital Trust, Tønsberg, Norway.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement